The day at a glance · 5 sections · 3 min read
Mood · Cautious
+25
Sentiment, −100 to +100
One Mind Festival Raised
$3.6M
Big Pharma & Biotech
DXCM 90-Day Return
27.79%+27.79%
MedTech & Devices
DXCM YTD Return
31.85%+31.85%
MedTech & Devices
Key driverPositive Phase 3 trial results for Amgen's dazodalibep in systemic Sjögren's disease drove biotech optimism, while FDA advisory support for Grail's multicancer blood test boosted diagnostics sentiment
Daily briefHealthcare· Money365.Market AI ·
Amgen Surges on Phase 3 Win; Grail Test Edges Toward FDA Nod
Dazodalibep data lifts Amgen 3.29%; FDA advisors back Grail multicancer screening; DexCom names new COO amid leadership overhaul
Big Pharma & Biotech
BullishAMGNBMYABBVLLY
Amgen (AMGN) reported positive topline Phase 3 OASIZ 301 results for dazodalibep in adults with moderate-to-severe systemic Sjögren's disease, showing statistically significant and clinically meaningful ESSDAI improvements sustained through Week 48 with generally mild to moderate side effects. The potential first-in-class CD40L antagonist could address an important unmet treatment need, as there are currently no approved disease-modifying therapies for persistent systemic Sjögren's. Shares rose following the announcement.
Bristol Myers Squibb (BMY) was added to the Zacks Rank #1 Strong Buy list, appearing on both strong buy and income stock rankings. The company participated as a presenting sponsor at the One Mind Music Festival, which raised over $3.6M to advance mental health research and discovery.
AbbVie (ABBV) announced a multi-year research collaboration with AI drug discovery startup Iambic Therapeutics, which filed for a U.S. IPO after raising money from NVIDIA and Qatar Investment Authority. Iambic will use its AI platform to discover and advance compounds for AbbVie under the partnership.
Eli Lilly (LLY) entered into a strategic research collaboration and license agreement with InnoCare Pharma to develop new medicines. InnoCare will leverage its proprietary drug discovery platform and extensive research experience to discover and advance compounds under the collaboration.
MedTech & Devices
NeutralISRGDXCM
Intuitive Surgical (ISRG) shares have declined 29% this year, though Wall Street analysts believe the robotic surgical systems leader's sell-off is overdone. The company remains a leader in surgical robotics despite the recent stock price weakness.
DexCom (DXCM) promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer, with his new role now including responsibility for global operations and quality. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift arrives as the company posts a 90-day share price return of 27.79% and year-to-date gain of 31.85%, though the 1-year total shareholder return of 29.97% contrasts with weaker longer-term performance.
FDA & Regulation
BullishGrail Stock (Week)
+35%+35%
ABT
FDA advisors recommended approval for the Grail multicancer blood test, with the stock rising 35% this week as the Food and Drug Administration considers the company's cancer blood test application. The advisory panel's positive recommendation marks a significant step toward potential approval of the screening technology.
Life Sciences Tools & Diagnostics
BullishOxidative Stress Assay Market 2035
$2.7B
Reusable Bioreactors Market 2035
$24.7B
Cell Culture Media Market 2025
$3.9B
Cell Culture Media Market 2035
$10.8B
TMO
Thermo Fisher Scientific (TMO) was featured in multiple market outlook reports covering the life sciences tools sector through 2035. The global oxidative stress assay market is projected to reach $2.7 billion by 2035, driven by chronic disease research, personalized medicine, and automated high-throughput kits. The global reusable bioreactors market is expected to reach $24.7 billion by 2035 as biologics manufacturing expands, with demand driven by biologics, personalized therapies, and vaccine production. The global cell culture media market was valued at $3.9 billion in 2025 and is projected to reach $10.8 billion by 2035, driven by serum-free formulations, biologics, and cell therapies.
Looking Ahead
NeutralMRK Close
$148.08-1.88%
AMGNMRNAPFEMRK
The UPLIZNA sales forecast and market analysis report projects growth through 2034, driven by new indications, global expansion, strong efficacy, differentiated CD19 targeting, and twice-yearly dosing, though competition is intensifying.
Moderna (MRNA) rallied to a fresh 52-week high amid positive company catalysts and improving investor sentiment.
Pfizer (PFE) scores 9/10 on technical and setup quality ratings, signaling strong trend momentum with a tight breakout setup.
Merck (MRK) closed at $148.08, marking a decline of 1.88% from the previous session.
Important Disclaimer — Not Investment Advice
Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.
Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest
Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.
- You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
- Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
- Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
- Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
- We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
- Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
- Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.
Full terms: Disclaimer · Terms of Service · Privacy Policy